Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

2796 results about "Lanthanide" patented technology

The lanthanide (/ˈlænθənaɪd/) or lanthanoid (/ˈlænθənɔɪd/) series of chemical elements comprises the 15 metallic chemical elements with atomic numbers 57–71, from lanthanum through lutetium. These elements, along with the chemically similar elements scandium and yttrium, are often collectively known as the rare earth elements.

Modified polymers prepared with lanthanide-based catalysts

InactiveUS6977281B1Active polymerLanthanide
A method for preparing a functionalized polymer comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated diene monomer with a lanthanide-based catalyst, where said pseudo-living polymer is characterized by having greater than about 85 percent of the polymer in the cis microstructure and less than about 3 percent of the polymer is in the 1,2- or 3,4-microstructure, and reacting the pseudo-living polymer with at least one functionalizing agent defined by the formula (I) or (II)
where Z is a substituent that will react or interact with organic or inorganic fillers; R1 is a single bond or a divalent organic group; R2 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R13 or R14; R3 is a single bond, a divalent organic group, or a trivalent organic group that forms a cyclic organic group with R4 or R5; R13 is a single bond, a divalent organic group, or a trivalent organic group that forms a cyclic organic group with R2 or R14; R4 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R3 or R5; R14 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R2 or R13; and R5 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R3 or R4; with the proviso that each group attached to the imino carbon is attached via a carbon atom and R1, R2, R3, R4, R5, R13, R14 and Z are substituents that will not protonate a pseudo-living polymer.
Owner:BRIDGESTONE CORP

Modified polymers prepared with lanthanide-based catalysts

InactiveUS20060025539A1Active polymerLanthanide
A method for preparing a functionalized polymer comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated diene monomer with a lanthanide-based catalyst, where said pseudo-living polymer is characterized by having greater than about 85 percent of the polymer in the cis microstructure and less than about 3 percent of the polymer is in the 1,2- or 3,4-microstructure, and reacting the pseudo-living polymer with at least one functionalizing agent defined by the formula (I) or (II) where Z is a substituent that will react or interact with organic or inorganic fillers; R1 is a single bond or a divalent organic group; R2 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R13 or R14; R3 is a single bond, a divalent organic group, or a trivalent organic group that forms a cyclic organic group with R4 or R5; R13 is a single bond, a divalent organic group, or a trivalent organic group that forms a cyclic organic group with R2 or R14; R4 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R3 or R5; R14 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R2 or R13; and R5 is a monovalent organic group or a divalent organic group that forms a cyclic organic group with R3 or R4; with the proviso that each group attached to the imino carbon is attached via a carbon atom and R1, R2 R3, R4, R5, R13, R14 and Z are substituents that will not protonate a pseudo-living polymer.
Owner:BRIDGESTONE CORP

Titanium carbonitride based metal ceramic based on high-entropy alloy binder phase and preparation method of metal ceramic

Disclosed is a titanium carbonitride based metal ceramic material based on a high-entropy alloy binder phase. The binder phase of the titanium carbonitride based metal ceramic material is high-entropy alloy, the hard phase of the titanium carbonitride based metal ceramic material is carbonitride solid solution, the high-entropy alloy binder phase includes at least four of ferrum, cobalt, nickel, chromium, aluminum, vanadium, titanium, copper, zirconium, molybdenum, manganese and rare earth elements, and the molar content ratio of each element ranges from 5% to 35%. In a preparation method, the titanium carbonitride based metal ceramic material based on the high-entropy alloy binder phase comprises raw materials including, in weight percent, 3-30% of the high-entropy alloy binder phase, 0-30% of second carbide powder and the balance carbonitride solid solution powder, the carbonitride solid solution powder includes at least one of Ti (Cx, N1-x), (Ti, M1...) and (Cx, N1-x), the M1 component of the (Ti, M1...) and (Cx, N1-x) includes at least one of W, Mo, Ta, Nb, V, Cr, Zr, Hf, Y and lanthanide, and 0<x<1 in the Ti (Cx, N1-x), (Ti, M1...) and (Cx, N1-x). The preparation method includes the process steps of (1) ball-milling mixing, (2) forming and (3) low-pressure sintering.
Owner:SICHUAN UNIV

Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof

One aspect of the present invention relates to a microsphere, comprising a hydrophilic polymer comprising a plurality of pendant anionic groups; a transition-metal, lanthanide or group 13-14 metal oxide, polyoxometalate or metal hydroxide or combination thereof; and a first radioisotope that emits a therapeutic β-particle. In certain embodiments, the microsphere further comprsies a second radioisotope that emits a diagnostic γ-ray; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, the microsphere is composed of polymer impregnated with zirconia bound to 32p as the source of the therapeutic β-emissions and 67Ga as the source of the diagnostic γ-emissions. Another aspect of the present invention relates to the preparation of a microsphere impregnated with a radioisotope that emits therapeutic β-particles and a radioisotope that emits diagnostic β-emitting radioisotope and a γ-emitting radioistope; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In certain embodiments, said microspheres are administered to the patient through a catheter. In another embodiment, the microsphere is combined with the radioisotopes at the site of treatment.
Owner:BIOSPHERE MEDICAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products